News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Diabetes, Infectious Diseases Early Focus of San Antonio Biomed Plan

David Holley, Xconomy Texas —  San Antonio — [Updated 12/14/17, 11:54 p.m. See below.] ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Saneron CCEL Therapeutics, Inc. Announces Clinical Supply And Research Collaboration Agreement With Texas Cord Blood Bank
May 31, 2012

TAMPA, Fla. - May 31, 2012 - Saneron CCEL Therapeutics, Inc. and the Texas Cord Blood Bank announced a clinical supply and research collaboration agreement to provide mononuclear cells from clinical grade cord blood for use in regenerative medicine research related to potential new Alzheimer's, ALS and stroke therapies. The Texas Cord Blood Bank is a division of the South Texas Blood & Tissue Center (STBTC), based in San Antonio, TX.

Under the agreement, the Texas Cord Blood Bank will research approaches for recovering and processing mononuclear cells from cord blood, building an inventory Saneron will use in clinical trials for possible therapies which could restore brain tissue in patients with these neurological disorders. The Texas Cord Blood Bank will provide the cord blood cells through another STBTC affiliate, GenCure, which focuses on providing cell and tissue services for regenerative medicine therapy and research.

Mary Beth Fisk, MT, CTBS, CQA; President & COO of STBTC, stated, "This opportunity to collaborate with Saneron and support research into potential new life-enhancing therapies is particularly gratifying because there are currently so few restorative treatments available for patients with these neurological disorders. Partnering to support this type of regenerative medicine research, which can have a huge impact on health care in the future, is the reason we established GenCure."

Nicole Kuzmin-Nichols, MBA; President & COO, added "We are very pleased to partner with the South Texas Blood & Tissue Center to provide clinical grade umbilical cord blood for potential future neurological applications such as Stroke, ALS, and Alzheimer's disease. As we move towards clinical trials, having access to a readily available supply of clinical grade U-CORD-CELLTM, Saneron's proprietary processed mononuclear cell fraction of cord blood, is crucial. We feel that STBTC has the both the expertise and volume of sample needed to be a key partner."

About Saneron CCEL Therapeutics, Inc.
Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company, focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of Saneron CCEL Therapeutics, Inc., Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.

About South Texas Blood & Tissue Center
The South Texas Blood & Tissue Center (STBTC) is a not-for profit community blood center specializing in a variety of services. Blood Services provides blood, plasma, platelets and other blood components to over 100 hospitals and clinics in 43 South Texas counties. STBTC has seven donor rooms in South Texas and conducts multiple mobile blood drives each week. GenCure, which focuses on regenerative medicine, includes Tissue Services, the National Marrow Donor Program and the Texas Cord Blood Bank.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

 

Stay informed. Subscribe to BioMed SA news alerts.